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Abstract The aim of the study was to evaluate the safety
and efﬁcacy of viscosupplementation with hylan G-F 20
in patients with mild to moderate osteoarthritis (OA)
presenting with persistent knee pain 4–12 weeks after
arthroscopic meniscectomy. A prospective, multi-centre,
open study was carried out in patients with pain due to OA
of the knee, not resolved by simple analgesics, 4–12 weeks
after undergoing arthroscopic meniscectomy. To be eligi-
ble, patients had to score C50 mm and B90 mm on both
walking pain and patient global assevssment visual ana-
logue scales (VAS; 0–100 mm) at baseline and be
radiologically diagnosed pre-operatively with OA grade I
or II on the Kellgren-Lawrence scale, with \50% joint
space narrowing. Patients received three intra-articular,
2 ml injections of hylan G-F 20 in the target knee with an
interval of 1 week between injections, and were followed
for 52 weeks. The primary efﬁcacy endpoint was the
change from baseline in the walking pain VAS score at
26 weeks. Secondary outcome measures were the walking
pain VAS scores at all other time points, the WOMAC
Index at all time points, and patient and physician global
assessment at all time points. The safety of the treatment
was assessed using adverse event (AE) reports. A total of
62 patients (mean age 55.4 years, 52% male) were enrol-
led. The mean walking pain VAS score decreased by
36.8 mm from baseline at 26 weeks (P\0.0001), and also
showed statistically signiﬁcant decreases (P\0.0001) at
all other time points. The change in WOMAC total and
subscale scores from baseline were statistically signiﬁcant
(P\0.0001) at all time points, as were the decreases in the
physician and patient global assessment VAS scores. There
were 18 target knee AEs (mostly pain and/or swelling and/
or effusion) in 12 patients (19%) considered to be at least
possibly related to treatment. The majority of these (78%)
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DOI 10.1007/s00167-008-0556-4were mild or moderate in intensity. One patient (1.6%)
experienced a serious adverse event (synovitis) in the target
knee that was considered possibly related to study treat-
ment. Hylan G-F 20 provides effective pain relief and
improves stiffness and physical function in patients with
mild to moderate OA presenting with persistent osteoar-
thritic pain 4–12 weeks after arthroscopic meniscectomy.
Symptomatic efﬁcacy was maximised at 12 weeks and
maintained at 26 and 52 weeks. The type (pain and/or
swelling and/or effusion) and the intensity (mostly mild/
moderate) of AEs reported in this study are similar to those
reported in other trials in different patient populations,
but the incidence was higher (19%). The risk/beneﬁt of
hylan G-F 20 in this particular population of patients is
favourable.
Keywords Osteoarthritis  Arthroscopy  Hylan 
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Introduction
Osteoarthritis (OA) is a chronic, degenerative disorder
associated with joint pain and loss of joint function. It is the
most common disease to affect synovial joints and is one of
the most frequently occurring chronic conditions.
The primary goal of treatment is the alleviation of pain,
leading to an improvement in joint function and quality of
life. Treatment options for knee OA include conservative
therapies (education, weight loss, physical therapy, etc.),
pharmacological therapies (simple analgesics, NSAIDs
(including COX-2s)), intra-articular injections (corticoste-
roids, viscosupplements) and surgical intervention (e.g.
arthroscopic debridement and lavage, meniscectomy, total
knee replacement (TKR)).
More than 90% of patients with symptomatic OA of the
knee have evidence of meniscal tears on magnetic reso-
nance imaging [6], and arthroscopic meniscectomy can
be used to treat patients who are unresponsive to more
conservative therapies, but are not yet TKR candidates.
However, the clinical beneﬁt of arthroscopic debridement
is unclear. In a double-blind study, Moseley et al. [11]
randomised 180 patients who underwent arthroscopic
debridement, arthroscopic lavage, or placebo surgery. At
no point during the 24-month follow-up did either of the
intervention groups report less pain or better function than
the placebo group. In contrast, Matsusue [10] reported that
87% of patients with grade I or II OA achieved ‘‘excellent’’
symptomatic relief from meniscal tear debridement. Until
such time as there is consensus on the clinical beneﬁt of
arthroscopic intervention for OA, it is likely that it will
remain in the orthopaedic armamentarium. However, a
sub-set of post-operative patients who have not gained
adequate symptomatic relief will continue to present with
persistent osteoarthritic pain several weeks or months after
the procedure. The causative factors behind this persistent
pain are unknown, but it is likely that the severity and
extent of OA, the degree of debridement performed and the
skill of the surgeon are major factors.
Viscosupplementation (intra-articular supplementation
of hyaluronic acid) is a well-established treatment option in
knee OA and is included in the professional guidelines for
treatment of the disease in this joint [2, 12] Several meta-
analyses have been conducted on the therapy class, which
agree broadly that viscosupplementation is effective and
safe [3, 5, 16].
Hylan G-F 20 (Synvisc
, Genzyme Corporation, MA,
USA) is a high molecular weight, cross-linked derivative of
hyaluronan. The safety and efﬁcacy of viscosupplementa-
tion with hylan G-F 20 in OA of the knee is supported by
prospective clinical trials [1, 13, 14, 17] and large retro-
spective studies [8, 15].
The use of viscosupplementation for the symptomatic
relief of knee OA in patients after arthroscopic menis-
cectomy has not been widely studied. Marshall [9]
reported on a retrospective series of 92 patients treated
with hylan G-F 20 after failing conservative treatments
and standardised arthroscopic debridement and injection
of IA steroid. The majority of these patients (77%) had
‘‘marked’’ or ‘‘severe’’ OA; 68% of patients did not go on
to TKR during the 2.5 year follow-up and were consid-
ered as ‘‘salvaged’’.
This study aimed to assess the efﬁcacy and safety
of viscosupplementation with hylan G-F 20 in patients
with mild or moderate knee OA who had failed to
achieve adequate symptomatic relief from arthroscopic
meniscectomy.
Materials and methods
Patients
Patients were enrolled at 10 centres across Europe: Bel-
gium (7), France (2) and Spain. The study protocol, patient
information and patient consent form were approved by the
independent ethics committee of each investigating centre.
Written, informed consent was obtained from each patient
prior to enrolment in the study.
To be considered eligible for inclusion, patients had to
present with osteoarthritic knee pain 4-12 weeks after
arthroscopic meniscectomy (mean time from meniscec-
tomy to the ﬁrst injection of hylan G-F 20 was 53 days
(range 27–107 days)) and must have had osteoarthritic
cartilage lesion(s) observed during arthroscopy. The loca-
tion and severity (Kellgren-Lawrence grade) of OA
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123observed on baseline X-rays is shown in Fig. 1. Each
arthroscopic surgery (Fig. 2) was performed by the authors,
all skilled and experienced in this technique.
Patients were considered eligible for inclusion if they
scored C50 mm and B90 mm on both the walking pain
and patient global assessment visual analogue scales (VAS)
(0–100 mm) at the screening visit. Patients were required
to have X-ray evidence (pre-operative anteroposterior
weight-bearing view (extension) + proﬁle and patello-
femoral at 30 classical (taken within 3 months of the
arthroscopic meniscectomy)) of osteoarthritis of the knee
(Kellgren-Lawrence grade I or II, \50% joint space
narrowing).
The main exclusion criterion was any surgery on the
cartilage during arthroscopic meniscectomy, except for
non-therapeutic, superﬁcial mechanical shaving of ﬁbril-
lations and/or resection of unstable ﬂaps in grade 2 and 3
lesions (grade 4 lesions were excluded), performed solely
for the purpose of cleaning the area to enable accurate
grading of the defect. Other exclusion criteria were: sig-
niﬁcant mechanical deﬁcit (e.g. valgus/varus[5%);
symptomatic contralateral knee OA; concomitant inﬂam-
matory joint disease (e.g. gout, rheumatoid arthritis);
history of sepsis in any joint; prior viscosupplementation in
the target knee; oral and/or parenteral glucocorticosteroids
or intra-articular corticosteroids in any joint within
3 months prior to enrolment.
Trial design
This was a prospective, multi-centre, open study conducted
between February 2002 and March 2005. A washout period
of 1–3 weeks was applied (adapted to half-life), com-
mencing at the screening visit, if patients had been taking
prohibited analgesic medications. Once any required
washout was completed and eligibility conﬁrmed, patients
presented for the baseline visit and received a single intra-
articular 2 ml injection of hylan G-F 20 using a strict
aseptic administration technique. Prior to each injection,
arthrocentesis was performed carefully, without injecting
local anaesthetic into the joint space, to remove any effu-
sion present. The suggested injection site was the lateral
tibiofemoral joint space in the extended knee.
No standard rehabilitation protocol was imposed. Med-
ication for pre-existing conditions was permitted. Also
permitted were: paracetamol (B4 g/day) except on the day
before and on the day of the follow-up visits; analgesics
and NSAIDs, other than COX-2 inhibitors, with a clearance
time of\8 h for pain other than OA in the study knee, or
for post-injection pain management, but not on the day
before or on the day of a study visit; aspirin (B 325 mg/
day) for anti-thrombotic prophylaxis; topical corticoste-
roids for skin problems, except at the study knee; inhaled
corticosteroids for asthma and allergic disease; non-phar-
macological therapy (e.g. physical therapy) if begun before
the study entry.
Prohibited medications were: analgesics and aspirin
except as described above; COX-2 inhibitors; oral or par-
enteral corticosteroids; corticosteroid injections in any
joint; topical analgesics at the study knee; therapeutic
treatment with oral or parenteral anticoagulants. Chon-
droprotective agents were not prohibited, but were not used
by any of the patients in the study. The use of all rescue and
concomitant medications and therapies were recorded in
the patient notes.
Patients returned to the investigational site at week 1
and week 2 for the remaining two injections of hylan G-F
20, and for follow-up and safety evaluations at week 12, 26
and 52. At each visit, walking pain, physician global
assessment and patient global assessment VAS were
completed, the WOMAC
TM questionnaire was ﬁlled out by
the patient, and concomitant therapy and adverse events
were recorded.
Outcome measures
All efﬁcacy analyses were performed on the intent-to-treat
(ITT) population, which was deﬁned as those patients who
58%
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Fig. 1 OA location and radiological severity (Kellgren-Lawrence
grade) at baseline (percentage of patients)
77%
53%
52%
0% 20% 40% 60% 80% 100%
Internal meniscectomy
Superficial mechanical shaving
Resection of unstable flaps
Fig. 2 Surgery performed at initial arthroscopy (percentage of
patients)
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123received at least one injection and for whom post-baseline
efﬁcacy data were present for at least the walking pain
VAS. The primary efﬁcacy outcome measure was the
change from baseline in walking pain VAS at 26 weeks.
Secondary efﬁcacy outcome measures were: change from
baseline in walking pain VAS at all other follow-up visits;
change from baseline in WOMAC osteoarthritis index
scores (pain (A), stiffness (B), physical functioning (C) and
composite scores) at all time points; change from baseline
in patient and physician global assessment VAS scores at
all time points.
The safety assessment was based on reports of adverse
events (AEs) collected between the signing of the informed
consent form and the completion of the ﬁnal follow-up visit
for each patient.
Results
Patients
The ITT population consisted of 62 patients. During the
study, seven patients were lost to follow-up, six withdrew
due to target knee AEs, two became ineligible to continue,
one withdrew consent and three patients discontinued from
the study for other reasons. A total of 43 patients (69%)
completed the study. Baseline demographics for the ITT
population are presented in Table 1.
Primary efﬁcacy endpoint
There was a statistically signiﬁcant decrease in the mean
score of the walking pain VAS from 65.0 mm at baseline to
28.0 at week 26 (P\0.0001; Fig. 3).
Secondary efﬁcacy endpoints
Walking pain VAS
The decreases from baseline in the walking pain VAS were
statistically signiﬁcant (P\0.0001) at all time points
(Fig. 3).
WOMAC Index
ChangesfrombaselineinthemeanWOMACscores(A,B,C
and composite) were statistically signiﬁcant (P\0.0001)
at all time points (Fig. 4).
Patient and physician global assessment
Changes from baseline in the mean patient and physician
global assessment scores were statistically signiﬁcant at all
time points (P\0.0001; Fig. 5).
Safety
Twelve patients (19%) reported a total of 18 target knee
AEs (arthralgia, joint swelling and joint effusion) that were
considered possibly (10 AEs) or probably (8 AEs) related
to the study treatment. These AEs were mostly considered
to be mild (1 AE) or moderate (13 AEs) in severity. One
serious target knee AE (‘‘synovitis’’ i.e. pain and swelling,
Table 1 Demographic data (ITT population)
Parameter ITT population
Number of patients 62
Gender: male/female, n (%) 32/30 (52/48)
Age (years): mean (SD) 55.4 (11.35)
Weight (kg): mean (SD) 81.6 (14.97)
Height (cm): mean (SD) 168.8 (9.64)
Body mass index (kg/m
2): mean (SD) 28.9 (6.26)
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Fig. 3 Walking pain mean VAS score at each time point (ITT
population)
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123which developed more than 2 months after the last injec-
tion of hylan G-F 20) was reported during the study and
was considered possibly related to the study treatment.
Three patients discontinued the study due to the occur-
rence of target knee AEs considered possibly or probably
study treatment related.
Conclusions
This is the ﬁrst study to evaluate prospectively the efﬁcacy
and safety of intra-articular injections of hylan G-F 20 in
patients with symptomatic knee OA unresponsive to simple
analgesics 4-12 weeks after arthroscopic meniscectomy.
Although deﬁnitive conclusions about efﬁcacy cannot
be drawn from this study due to its open label design, hylan
G-F 20 was effective at signiﬁcantly reducing the pain
associated with knee OA. Statistically signiﬁcant changes
from baseline were seen consistently in all primary and
secondary efﬁcacy outcome measures at all time points.
In the ITT population, reduction in pain was apparent
from as soon as 7 days after injection, was maximised at
12 weeks and maintained at 26 and 52 weeks. These
results reﬂect those reported in other studies in patients
with knee OA, where the symptomatic relief obtained by
patients outlasts substantially the product’s residence time
in the joint, thus supporting the hypothesis that viscosup-
plementation achieves its therapeutic effect by restoring the
rheology of the joint temporarily [4].
The safety proﬁle of hylan G-F 20 in knee OA is already
supported by clinical literature. In the largest study con-
ducted to date, Kemper et al. [7] assessed the safety of the
treatment in 4,253 patients and reported AE rates of 4.2%
of patients and 2.4% of injections. The types of AEs seen in
our study were consistent with those seen in Kemper et al.
and described in the product labelling (transient
post-injection pain and/or swelling and/or effusion). The
reason for the higher incidence of these AEs observed
in this particular population of patients compared to
previously published data is unknown. However, no new
safety concerns were raised in this study and most AEs
experienced were transient and of mild or moderate
intensity.
We conclude that viscosupplementation with hylan G-F
20 has a favourable risk/beneﬁt proﬁle in patients with
symptomatic knee OA presenting with persistent pain after
arthroscopic meniscectomy.
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